Has James Trotter, MD received payments from drug or device companies?

Yes. Drug and device makers reported $15,195 in general payments to James Trotter, MD across 50 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean James Trotter, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about James Trotter, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

James Trotter, MD

Gastroenterology · Murray, UTNPI 1225128903

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $14,344 of the $15,195 with a category attached, or 94.4%. 10 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 32.9% of the total. Reporting peaked in 2020 at $8,177 and has fallen 72.8% since, to $2,228 in 2024. Among gastroenterology clinicians in UT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,195in general payments, 2019–2025

Across 50 payments — averaging $303.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mallinckrodt Hospital Products Inc.$5K
Modernatx, Inc.$4K
Organox Ltd$3K
Gilead$2K
AbbVie$471
Mallinckrodt Enterprises LLC$73
plus $126 from 4 others

$1,962,256in research payments, 2019–2025

Across 229 payments — averaging $8568.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Intercept Pharmaceuticals, Inc.$1.1M
Gilead$478K
Intercept Pharma Europe Ltd.$255K
La Jolla Pharmaceutical Company$55K
Mallinckrodt Hospital Products Inc.$26K
E.r. Squibb & Sons, L.L.C.$18K
plus $20K from 3 others

What the payments were for

Consulting fees$14,34494%
Food & beverage$8516%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mallinckrodt Hospital Products Inc.	1	$5,000
Modernatx, Inc.	5	$4,284
Organox Ltd	1	$3,000
Gilead	10	$2,241
AbbVie	26	$471
Mallinckrodt Enterprises LLC	1	$73
Shionogi Inc	2	$45
Dova Pharmaceuticals	2	$33
GI Supply, Inc.	1	$32
Optos, Inc.	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vemlidy$2,060

How this compares

$15,195 in reported general payments places this provider in the 90th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah →

Medicare billing

Part B allowed, 2024

$26,797

Medicare patients

182

Services billed

305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XifaxanRifaximin	25	$88,281
Mycophenolic AcidMycophenolate Sodium	37	$20,912
Sirolimus	21	$16,880
Ursodiol	60	$9,773
Tacrolimus	60	$8,516
Cyclosporine ModifiedCyclosporine, Modified	21	$4,394
Tenofovir Disoproxil Fumarate	13	$2,067
Azathioprine	32	$1,053
Neomycin Sulfate	22	$783
Spironolactone	43	$716
Lactulose	14	$607
Pantoprazole Sodium	19	$267
Prednisone	38	$247
Furosemide	39	$223
Ciprofloxacin Hcl	12	$101

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Murray

Jonathan WongMurray$7K
Sandeep SinghMurray$5K
Terry BoxSalt Lake City$302K
Richard GilroySalt Lake City$192K
Kyle EliasonOgden$128K
Umaprasanna KarnamRiverton$120K
Kathryn PetersonSalt Lake City$111K
John Erikson YapSt George$94K
Chad GonzalesOgden$25K
Chad KawaProvo$22K

See the full list for Utah →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →